HSBC reported a sharper-than-expected 86% fall in pretax profit for the third quarter as the British lender took a $1.7bn loss on the sale of its Brazilian unit and it also pointed to customer compensation in America and currency moves for the fall in profits.
The bank’s reported pretax profit was $843 million in the September quarter, down from $6.1 billion in the same period a year ago, HSBC said in a Hong Kong stock exchange filing on Monday.
Richemont reported a 51% fall in six-month profit to €540 million ($599 million). Sales fell 13% to €5.1 billion. In September, Richemont had warned profit would be down about 45%.
“Sales and profits for the six-month period ended Sept. 30, 2016 were significantly below the prior year’s level, reflecting the difficult global environment, the exceptional inventory buybacks and challenging comparative figures in the first half of the previous financial year,” Executive Chairman Johann Rupert said in a statement.
Credit Suisse has reported an unexpected net profit of 41 million Swiss francs ($42.2m) for the third quarter. Profit fell 95% from 779 million Swiss francs in the same quarter last year, but the company beat analysts’ forecasts who expected 150 million francs loss.
It is the second consecutive quarter in which Credit Suisse has surprised the market with a profit after a rocky start to chief executive Tidjane Thiam’s turnaround plan for the bank.
The bank also said its core tier 1 common equity – a measure of the amount of capital it has set aside to absorb business and market losses – rose to 12% in Q3 from 11.8% in the previous three month period.
The private bank group J. Safra Sarasin Group announced that it has acquired Credit Suisse Gibraltar Limited. The transaction strengthens the institution’s presence on the Rock where the Group operates since 2001 and is determined to expand its position.
The bank will operate under the new name of Bank JSS (Gibraltar) Ltd. and will continue to provide wealth management solutions to customers both private and institutional.
The OC Oerlikon industrial group reported operating profit EBIT decline of 47.1% in the third quarter compared to the same period of 2015, to 37 million francs. After nine months, EBIT came to 105 million, a decrease of 53.9% compared to a year ago.
Sales decreased by 13.4% to 549 million in the third quarter, and by almost 15% to 1.72 billion, informs in a statement the Pfäffikon-based group.
BSI was acquired by EFG International: the agreement was closed for 1.06 billion francs as announced by the Zurich-based institute, 270 million less than expected and announced in February. The total price is made up of 575 million francs in cash, 86.2 million EFG shares valued at 454 million francs and 31 million francs of AT1 instruments issued by EFG International, as the company reported in a statement.
The US pharmaceutical giant Pfizer has closed the third quarter with results below expectations. The net profit falls 38% to 1.32 billion dollars from the prior year’s $2.130 billion while quarterly revenues grew by 7.93% to $ 13.045 billion, the forecast was $ 13.05 billion.
Chinese chemical giant ChemChina has extended the deadline of its offer to purchase the agrochemical group Syngenta Basel, until January 5. The previous deadline was to expire next Tuesday.
It is the fourth time that the Chinese group extends its tender offer (Opa): the giant state had already been extended to May its initial offer until July 18 and then to July until 13 September and until September 8th of November.
For qualified investors / professional clients only
In order to proceed, you must confirm that you are a qualified investor based in Switzerland
The information contained in this section have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document.
Before investing in a product please read the latest prospectus carefully and thoroughly and note that funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming units. Commissions and costs have a negative impact on performance. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. The details and opinions contained in this document are provided without any guarantee or warranty and are for the recipient's personal use and information purposes only